CN115916184A - 包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂 - Google Patents

包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂 Download PDF

Info

Publication number
CN115916184A
CN115916184A CN202180042209.2A CN202180042209A CN115916184A CN 115916184 A CN115916184 A CN 115916184A CN 202180042209 A CN202180042209 A CN 202180042209A CN 115916184 A CN115916184 A CN 115916184A
Authority
CN
China
Prior art keywords
once
days
transdermal
pain
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042209.2A
Other languages
English (en)
Chinese (zh)
Inventor
F·M·普拉科吉安尼斯
T·莱瑟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spear Therapy Co ltd
Original Assignee
Spear Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spear Therapy Co ltd filed Critical Spear Therapy Co ltd
Publication of CN115916184A publication Critical patent/CN115916184A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180042209.2A 2020-04-20 2021-04-20 包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂 Pending CN115916184A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063012428P 2020-04-20 2020-04-20
US63/012,428 2020-04-20
PCT/IB2021/000261 WO2021214545A1 (en) 2020-04-20 2021-04-20 Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain

Publications (1)

Publication Number Publication Date
CN115916184A true CN115916184A (zh) 2023-04-04

Family

ID=78270322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042209.2A Pending CN115916184A (zh) 2020-04-20 2021-04-20 包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂

Country Status (8)

Country Link
US (2) US20210346310A1 (https=)
EP (1) EP4110325A4 (https=)
JP (1) JP2023523155A (https=)
CN (1) CN115916184A (https=)
AU (1) AU2021259495A1 (https=)
CA (1) CA3178878A1 (https=)
MX (1) MX2022012415A (https=)
WO (1) WO2021214545A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118045221A (zh) * 2024-02-04 2024-05-17 广东云曌医疗科技有限公司 一种水凝胶敷料及其制备方法和应用

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
CN117337174A (zh) * 2020-12-03 2024-01-02 长矛治疗股份有限公司 用于治疗癌症的包含cbd或thc的透皮药物制剂
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN117545478A (zh) * 2021-04-22 2024-02-09 长矛治疗股份有限公司 用于治疗慢性疼痛的透皮药物制剂
EP4366728A4 (en) * 2021-07-08 2025-05-14 Innocan Pharma Ltd. COMPOSITIONS FOR THE TREATMENT OF DIABETIC SYMPTOMS
WO2023012691A1 (en) * 2021-08-03 2023-02-09 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
EP4426290A4 (en) * 2021-11-02 2025-10-08 Schedule 1 Therapeutics Inc USE OF CANNABINOID COMPOSITIONS TO TREAT PAIN ASSOCIATED WITH SMALL FIBER NEUROPATHY
EP4558135A1 (en) * 2022-07-21 2025-05-28 Pike Therapeutics Inc. Continuous delivery systems comprising a cannabinoid and medicinal uses thereof
US11826342B1 (en) * 2022-09-27 2023-11-28 Saaransh Mahna Cannabidiol formulation for alleviating pain and a method of manufacturing
WO2026018119A1 (en) * 2024-07-16 2026-01-22 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
CN101815697A (zh) * 2007-07-30 2010-08-25 奥特兰兹公司 大麻二酚前药、包括大麻二酚前药的组合物及其使用方法
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
WO2016144376A1 (en) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
CA3076929A1 (en) * 2017-09-25 2019-03-28 Canopy Health Innovations Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia
WO2020014200A1 (en) * 2018-07-09 2020-01-16 Volker Berl Stabilized formulations of cannabinoid compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9095563B2 (en) * 2013-09-26 2015-08-04 Ronald D. Sekura Topical treatments incorporating Cannabis sp. derived botanical drug product
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
CA2976004C (en) * 2015-02-05 2020-06-02 Colorado Can Llc Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
CN108697665A (zh) * 2015-09-30 2018-10-23 乔治·爱德华·霍格 局部镇痛性疼痛缓解制剂、其制备和使用方法
WO2018083695A2 (en) * 2016-11-02 2018-05-11 Tikun Olam Ltd Combination therapies
US10702495B2 (en) * 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
FR3064334B1 (fr) * 2017-03-24 2021-05-14 Dcns Energies Presse-etoupe de traversee etanche d'un orifice d'une cloison
US12357604B2 (en) * 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
BR112020014253A2 (pt) * 2018-01-12 2020-12-08 Nutrae, LLC Formulações de canabinóides encapsuladas para administração oral
US20210015740A1 (en) * 2019-03-04 2021-01-21 Michael Harvey Greenspan Topical cannabinoid compositions, delivery systems, and uses for pain relief
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
CN101815697A (zh) * 2007-07-30 2010-08-25 奥特兰兹公司 大麻二酚前药、包括大麻二酚前药的组合物及其使用方法
US20120202891A1 (en) * 2009-04-29 2012-08-09 University Of Kentucky Research Foundation Cannabinoid-Containing Compositions and Methods for Their Use
WO2016144376A1 (en) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
CA3076929A1 (en) * 2017-09-25 2019-03-28 Canopy Health Innovations Compositions comprising cannabidiol, tetrahydrocannabinol, terpenes, and flavonoids and use thereof in the treatment of insomnia
WO2020014200A1 (en) * 2018-07-09 2020-01-16 Volker Berl Stabilized formulations of cannabinoid compositions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118045221A (zh) * 2024-02-04 2024-05-17 广东云曌医疗科技有限公司 一种水凝胶敷料及其制备方法和应用
CN118045221B (zh) * 2024-02-04 2024-07-19 广东云曌医疗科技有限公司 一种水凝胶敷料及其制备方法和应用

Also Published As

Publication number Publication date
EP4110325A4 (en) 2024-07-03
CA3178878A1 (en) 2021-10-28
JP2023523155A (ja) 2023-06-02
US20210346310A1 (en) 2021-11-11
AU2021259495A1 (en) 2022-10-27
EP4110325A1 (en) 2023-01-04
US20250248948A1 (en) 2025-08-07
MX2022012415A (es) 2023-02-09
WO2021214545A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CN115916184A (zh) 包含大麻二酚和/或四氢大麻酚的治疗慢性疼痛的透皮和/或局部药物制剂
CN116075296A (zh) 用于治疗多发性硬化症的透皮药物制剂
CN115884761A (zh) 大麻素的透皮药物制剂
JP7670700B2 (ja) 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
CN114555068A (zh) 大麻二酚的透皮给药
UA125040C2 (uk) Фенітоїн для місцевого застосування для використання при лікуванні периферичного нейропатичного болю
CN117545478A (zh) 用于治疗慢性疼痛的透皮药物制剂
JP2024514843A (ja) 発作性疾患を治療するための医薬組成物及び方法
KR20070059079A (ko) 경피 페로스피론 투여용 의약적 조성물
WO2019135125A1 (en) Semi-solid dosage form for topical application
CN117460503A (zh) 大麻二酚的透皮递送
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination